Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
Tohi Y, Ishikawa R, Kato T, Miyakawa J, Matsumoto R, Mori K, Mitsuzuka K, Inokuchi J, Matsumura M, Shiga K, Naito H, Kohjimoto Y, Kawamura N, Inoue M, Kinoshita H, Hashimoto K, Goto K, Haba R, Kakehi Y, Sugimoto M. Tohi Y, et al. Among authors: matsumoto r. Int J Clin Oncol. 2023 Feb;28(2):299-305. doi: 10.1007/s10147-022-02277-8. Epub 2022 Dec 6. Int J Clin Oncol. 2023. PMID: 36472710
Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan.
Matsumoto R, Abe T, Ishizaki J, Kikuchi H, Harabayashi T, Minami K, Sazawa A, Mochizuki T, Akino T, Murakumo M, Osawa T, Maruyama S, Murai S, Shinohara N. Matsumoto R, et al. Jpn J Clin Oncol. 2018 Aug 1;48(8):771-776. doi: 10.1093/jjco/hyy094. Jpn J Clin Oncol. 2018. PMID: 29939285 Free PMC article.
Comparative study of lymph node dissection, and oncological outcomes of laparoscopic and open radical nephroureterectomy for patients with urothelial carcinoma of the upper urinary tract undergoing regional lymph node dissection.
Abe T, Kondo T, Harabayashi T, Takada N, Matsumoto R, Osawa T, Minami K, Nagamori S, Maruyama S, Murai S, Tanabe K, Shinohara N. Abe T, et al. Among authors: matsumoto r. Jpn J Clin Oncol. 2018 Nov 1;48(11):1001-1011. doi: 10.1093/jjco/hyy128. Jpn J Clin Oncol. 2018. PMID: 30272169 Free PMC article.
The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study.
Tohi Y, Kato T, Matsumoto R, Shinohara N, Shiga K, Yokomizo A, Nakamura M, Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K, Inokuchi J, Eto M, Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M. Tohi Y, et al. Among authors: matsumoto r. Int J Clin Oncol. 2020 Dec;25(12):2107-2114. doi: 10.1007/s10147-020-01761-3. Epub 2020 Aug 8. Int J Clin Oncol. 2020. PMID: 32770439
Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN.
Hirama H, Sugimoto M, Miyatake N, Kato T, Venderbos LDF, Remmers S, Shiga K, Yokomizo A, Mitsuzuka K, Matsumoto R, Osawa T, Abe T, Sasaki H, Egawa S, Ninomiya I, Hashine K, Roobol MJ, Kakehi Y. Hirama H, et al. Among authors: matsumoto r. World J Urol. 2021 Jul;39(7):2491-2497. doi: 10.1007/s00345-020-03494-4. Epub 2020 Oct 20. World J Urol. 2021. PMID: 33079252
Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study.
Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M. Tohi Y, et al. Among authors: matsumoto r. Urol Oncol. 2022 Feb;40(2):56.e9-56.e15. doi: 10.1016/j.urolonc.2021.05.003. Epub 2021 Jun 8. Urol Oncol. 2022. PMID: 34112576
Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN.
Kato T, Hirama H, Mitsuzuka K, Maruyama S, Sasaki H, Saito T, Matsumoto R, Sakamoto S, Sakai Y, Fukuhara H, Naya Y, Tsukino H, Hara I, Ogawa O, Hashine K, Fumimasa F, Yokomizo A, Tohi Y, Kakehi Y, Sugimoto M. Kato T, et al. Among authors: matsumoto r. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):666-671. doi: 10.1038/s41391-021-00422-4. Epub 2021 Jul 12. Prostate Cancer Prostatic Dis. 2022. PMID: 34253849
Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.
Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M. Tohi Y, et al. Among authors: matsumoto r. Int J Clin Oncol. 2022 Jan;27(1):194-201. doi: 10.1007/s10147-021-02041-4. Epub 2021 Oct 2. Int J Clin Oncol. 2022. PMID: 34599725
Correction to: The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study.
Tohi Y, Kato T, Matsumoto R, Shinohara N, Shiga K, Yokomizo A, Nakamura M, Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K, Inokuchi J, Eto M, Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M. Tohi Y, et al. Among authors: matsumoto r. Int J Clin Oncol. 2022 Apr;27(4):827. doi: 10.1007/s10147-022-02145-5. Int J Clin Oncol. 2022. PMID: 35237924 No abstract available.
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.
Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group. Shiota M, et al. Among authors: matsumoto r, matsumoto h. Cancer Sci. 2022 Jul;113(7):2386-2396. doi: 10.1111/cas.15383. Epub 2022 May 17. Cancer Sci. 2022. PMID: 35485635 Free PMC article.
1,154 results